Home » Authors » Aaron Lorenzo

Aaron Lorenzo

Articles

ARTICLES

Phytobiotech Raises C$17M For Plant-Derived Molecules

Sep. 26, 2002

By Aaron Lorenzo

StemCells Cutting Back To Focus On Neural, Liver Disease

Sep. 24, 2002

By Aaron Lorenzo

StemCells Cutting Back To Focus On Neural, Liver Disease

Sep. 24, 2002

By Aaron Lorenzo

eXegenics, IDDS Merging Via Stock Deal Valued At $46M

Sep. 23, 2002

By Aaron Lorenzo

eXegenics, IDDS Merging Via Stock Deal Valued At $46M

Sep. 23, 2002

By Aaron Lorenzo

Endovasc Creates Subsidiaries For Two Late-Stage Products

Sep. 20, 2002

By Aaron Lorenzo

Endovasc Creates Subsidiaries For Two Late-Stage Products

Sep. 20, 2002

By Aaron Lorenzo

Cellegy Resurrects Cellegesic, Set To Begin Third Phase III

Sep. 10, 2002

By Aaron Lorenzo

Cellegy Resurrects Cellegesic, Set To Begin Third Phase III

Sep. 10, 2002

By Aaron Lorenzo

LION Cutting Back On Drugs To Focus On Support Systems

Sep. 9, 2002

By Aaron Lorenzo

View All Articles by Aaron Lorenzo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...